India approves first dengue vaccine for individuals aged 4 to 60 years
Summary
Takeda’s two-dose QDENGA vaccine, approved by the Drug Controller General of India, can be administered without prior dengue screening and is designed to protect against all four dengue virus serotypes
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For India, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketIndia
- ImpactMedium (50/100)
- SignalNews